| Term 
 
        | Two types of strokes: 
 Which is most common?
 
 Which is most severe?
 |  | Definition 
 
        | ischemic hemorrhagic (less common/most debilitating)
 |  | 
        |  | 
        
        | Term 
 
        | How is each type of stroke named? |  | Definition 
 
        | Hemorrhagic is named by bleed location 
 Ischemic is named by etiology
 |  | 
        |  | 
        
        | Term 
 
        | The pathway of an ischemic stroke |  | Definition 
 
        | 1. Occlusion 2. Ischemia
 3. Toxic cascade
 |  | 
        |  | 
        
        | Term 
 
        | What events lead to the occlusion? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | In ischemia what is occurring to the tissue? |  | Definition 
 
        | Reduced nutrient/waste exchange Anaerobic metabolism
 Ion shifts
 |  | 
        |  | 
        
        | Term 
 
        | Explain the toxic cascade |  | Definition 
 
        | 1. Excess of excitatory A.A. 2. Inflammation mediators
 3. Free radical production
 |  | 
        |  | 
        
        | Term 
 
        | What co-morbidities are associated with a hemorrhagic stroke |  | Definition 
 
        | Trauma Infection
 Uncontrolled HTN
 tumor
 Abnormal vessels
 |  | 
        |  | 
        
        | Term 
 
        | Ultimately a hemorrhagic stroke manifests as... |  | Definition 
 
        | Increased cranial space volume |  | 
        |  | 
        
        | Term 
 
        | What are the 3 Cincinnati Pre-hospital Stroke Test criteria? |  | Definition 
 
        | 1. Facial droop 2. Arm drift
 3. Abnormal speech
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | 1. CT scan (quick) 2. MRI (longer)
 |  | 
        |  | 
        
        | Term 
 
        | Ways to prevent a stroke from ever occuring |  | Definition 
 
        | 1. BP control 2. No smoking
 3. Anti-platelet therapy if appropriate
 4. Anti-coagulation therapy if CHADS >/= 2, or PT has A. fib
 5. Statin therapy if needed
 |  | 
        |  | 
        
        | Term 
 
        | Describe the line drawn across the body that determines if a pt will need anti-platelet or anti-coagulation therapy |  | Definition 
 
        | Clot above shoulders = anti-platelet Clot below shoulders = anti-coagulation
 |  | 
        |  | 
        
        | Term 
 
        | The CHADS scale is for what type of PTs? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | 1 - CHF 1 - HTN
 1 - Age >/= 75
 1 - Diabetes
 2 - Stroke/TIA (previous)
 
 @ or more anti-coagulation therapy
 |  | 
        |  | 
        
        | Term 
 
        | When is it okay to use rt-PA (Alteplase)? |  | Definition 
 
        | ISCHEMIC stroke ONLY Within the first 4 hours
 |  | 
        |  | 
        
        | Term 
 
        | What are six contraindications to using rt-PA (Alteplase)? |  | Definition 
 
        | 1. Symptoms have began to improve 2. Heparin within the last 48 hours
 3. Active internal bleeding
 4. Intra cranial surgery in the last 3 months
 5. Seizure occurred at the stroke's 6. onset
 BP > 185/110
 |  | 
        |  | 
        
        | Term 
 
        | How is rt-PA (Alteplase) dosed? |  | Definition 
 
        | 0.9mg/kg IV 
 10% bolus 90% infusion over 1 hr
 
 Max 90mg
 |  | 
        |  | 
        
        | Term 
 
        | How is rt-PA (Alteplase) monitored |  | Definition 
 
        | Hours 1: every 15min Hours 2-7: every 30min
 Hours 8-24: every hour
 Hours 25+: every shift
 |  | 
        |  | 
        
        | Term 
 
        | What is monitored after rt-PA (Alteplase) administration |  | Definition 
 
        | 1. Bleeding 2. Neurological recovery
 3. PT/INR/aPTT
 4. Hemoglobin/Hematocrit
 5. Cranial CT scan
 |  | 
        |  | 
        
        | Term 
 
        | What trial confirmed rt-PA to be effective in ischemic stroke treatment? |  | Definition 
 
        | NINDS - Nat. Institute of Neurological Disorders |  | 
        |  | 
        
        | Term 
 
        | BY how much does rt-PA improve ischemic stroke outcomes according to the NINDS trial? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What trial determined Aspirin to be an effective anti-platelet treatment? |  | Definition 
 
        | The international stroke trial |  | 
        |  | 
        
        | Term 
 
        | What trial determined that pts on aspirin had better outcomes? |  | Definition 
 
        | CAST (Chinese Acute Stroke Trial) [160-325mg used in trial]
 |  | 
        |  | 
        
        | Term 
 
        | What is the role of uf-heparin/LMWH in stroke pts? |  | Definition 
 
        | 3-4 days after rt-PA if the pt has some paralysis, then they need uf-hep/LMWH to prevent a VTE |  | 
        |  | 
        
        | Term 
 
        | What is the dosing of of uf-heparin/LMWH? |  | Definition 
 
        | UFH = 5000u SQ q8-12h Enoxaparin = 40mg SQ qDAY
 Dalteparin 2500u SQ qDAY
 |  | 
        |  | 
        
        | Term 
 
        | What single factor makes the largest difference in stroke recurrence? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What BP therapy is preferred in post stroke pts? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How is dyslipidemia treated post stroke? |  | Definition 
 
        | 80mg atorvastatin regardless of baseline LDL |  | 
        |  | 
        
        | Term 
 
        | The brand name drug Aggrenox consist of what combination of drugs? |  | Definition 
 
        | 200mg Dipyridamole + 25mg Aspirin |  | 
        |  | 
        
        | Term 
 
        | What trial showed a dipyridamole/aspirin combination drug like Aggrenox would be an effective treatment? |  | Definition 
 
        | ESPS-2 European Stroke Prevention Study-2 |  | 
        |  | 
        
        | Term 
 
        | Describe the results of the CAPRIE (Clopidogrel vs. Aspirin in Pt Risk for Ichemic Events) trial |  | Definition 
 
        | Clopidogrel is less likely to cause MI and GI hemorrhage |  | 
        |  | 
        
        | Term 
 
        | In the CAPRIE trail clopidogrel beat out plain aspirin, but what was discovered in the ProFESS trial? |  | Definition 
 
        | Aggrenox (cdipyridamole/aspirin combo drug) was equivalent to clopidogrel alone |  | 
        |  | 
        
        | Term 
 
        | The MATCH (MGMT of atherothrombis w/ Clopidogrel in High riskj prs) trial compared Clopidogrel alone vs. a clopidogrel/aspirin combo products.  What was the result in these pts? |  | Definition 
 
        | The combination of clopidogrel and aspirin greatly reduced hemorragic strokes & life threatening bleeding |  | 
        |  | 
        
        | Term 
 
        | Anti-platelet therapy should be monitored in 3 ways |  | Definition 
 
        | 1. Signs/symptoms of bleeding 2. Signs/symptoms of stroke
 3. CBC
 |  | 
        |  | 
        
        | Term 
 
        | How are direct XA inhibitors (rivaroxaban/apixaban) different from WARFARIN in anti-coagulation therapy? |  | Definition 
 
        | 1. Cost more 2. unable to monitor
 3. no antedote
 4. Higher risk of MI
 |  | 
        |  | 
        
        | Term 
 
        | Which direct xa inhibitor has a storage issue? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Normal 150mg PO BID Renal Reduced 75mg PO BID
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Normal 20mg PO qDAY Renal reduced 15mg PO qDAY
 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Normal 5mg PO BID High risk 2.5mg BID
 
 (High risk = age>/= 80, =/< 60kg, SCr>/=1.5mg/dL)
 |  | 
        |  | 
        
        | Term 
 
        | The RELY study determined |  | Definition 
 
        | The efficacy/safety of dabigatran to be greater than WARFARIN |  | 
        |  | 
        
        | Term 
 
        | The Rocket-AF study determined |  | Definition 
 
        | The efficacy/safety of drivaroxaban to be greater than WARFARIN |  | 
        |  | 
        
        | Term 
 
        | The ARISTOTLE study determined |  | Definition 
 
        | The efficacy/safety of apixiban to be greater than WARFARIN |  | 
        |  |